Foundation Makes Milestone Payment to EPIX Pharmaceuticals
| 1 min read

The CF Foundation announced today that EPIX Pharmaceuticals, Inc. achieved another milestone in its collaborative effort to discover CF therapies. EPIX will receive a $500,000 milestone payment for successfully screening drug candidates that target the delta F508 mutation of CFTR, the key protein associated with cystic fibrosis. Delta F508 is the most common mutation in CF patients.  

Previously, EPIX developed a three-dimensional computer model of CFTR, which allows researchers to identify specific areas within CFTR that are potential targets for new drugs.

“Our collaboration with EPIX continues to yield important scientific advances,” said Robert J. Beall, Ph.D., president and CEO of the Foundation. “We are pleased with the tangible results and we look forward to continuing our work together as we focus on our goal of creating new therapies to treat CF.”

This milestone payment brings the total amount achieved under this collaboration to $5 million.

Share this article
Topics
About the CF Foundation | Our Research Approach
Recent news
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes
News | 5 min read
CF Foundation Honors the Legacy of Joe O’Donnell
News | 4 min read
CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 
News | 2 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe